bioAffinity Technologies

[bioAffinity Technologies @bioAffinity]

Knowing a nodule’s status early allows clinicians to make clear decisions. CyPath® Lung provides actionable results that continued surveillance or definitive intervention, helping ensure patients receive the right care at the right time. https://t.co/Okp2Bq5YTn $BIAF

[bioAffinity Technologies @bioAffinity]

Mark your calendars! The @SABronchoscopy will host a live webinar on CyPath® Lung’s expanding role in pulmonary, oncology and surgical practices for the detection and management of early-stage lung cancer.

📅 Tuesday, June 16, at 7 p.m. ET

https://t.co/2hqi2wGdA3 $BIAF

[bioAffinity Technologies @bioAffinity]

When indeterminate nodules are detected, actionable data is key. CyPath® Lung delivers early assessment of malignancy risk, helping clinicians determine if watchful waiting is appropriate or if more aggressive procedures are called for. https://t.co/Okp2Bq5YTn $BIAF

[bioAffinity Technologies @bioAffinity]

Pulmonary nodule management requires timely information. CyPath® Lung provides timely actionable results, allowing care teams to determine next steps and reassure patients. https://t.co/Okp2Bq5YTn $BIAF

[bioAffinity Technologies @bioAffinity]

New patent for $BIAF!

Mexico is granting a new patent for our use of flow cytometry for earlier lung cancer detection. The Mexican patent expands global IP protection for CyPath® Lung, our proprietary, noninvasive test for lung cancer. https://t.co/ocEy3bHW94

[bioAffinity Technologies @bioAffinity]

Only about 1 in 4 eligible Americans were up to date with #lungcancerscreening in 2024, according to a research letter posted on #JAMA.
Early detection matters. #CyPathLung can make a difference.
#LungCancerAwareness #EarlyDetection #LungHealth #Pulmonology #CancerPrevention

[bioAffinity Technologies @bioAffinity]

CyPath® Lung helps clinicians act with certainty on pulmonary nodules. By providing actionable results, it supports difficult care decisions and give patients more confident guidance. https://t.co/Okp2Bq5YTn $BIAF

[bioAffinity Technologies @bioAffinity]

bioAffinity Technologies appreciates the opportunity to collaborate with the American Lung Association to advance lung health initiatives.
#AmericanLungAssociation #lunghealth #ATS2026 #CyPathLung #lungcancer #biotech

[bioAffinity Technologies @bioAffinity]

Congrats to this outstanding team for a great #ATS2026. #CyPathLung was well represented by your expertise, energy and teamwork.
#lungcancer #pulmonology #LungCancerAwareness #PulmonaryMedicine #HealthcareInnovation #Biotech #Diagnostics #Teamwork #ConferenceSuccess #ProudTeam

[bioAffinity Technologies @bioAffinity]

Decisions about pulmonary nodules are easier with early clarity. CyPath® Lung provides clinicians with actionable results, helping guide watchful waiting or intervention and supporting better patient outcomes.

https://t.co/Okp2Bq5YTn $BIAF

[bioAffinity Technologies @bioAffinity]

A busy day at #ATS2026! Great conversations with pulmonologists, researchers & healthcare leaders about advancing early #lungcancer detection and the role of noninvasive diagnostics like #CyPathLung.
#EarlyDetection #Pulmonology #Innovation

[bioAffinity Technologies @bioAffinity]

CyPath® Lung, our noninvasive, AI-powered diagnostic test with at-home sample collection, is helping advance earlier lung cancer risk assessment and support clinical decision-making.
#ATS2026 #LungCancer #EarlyDetection #Pulmonology #Innovation #CyPathLung

[bioAffinity Technologies @bioAffinity]

🫁 Join Society for Advanced Bronchoscopy June 16, 7 PM ET for webinar on managing pulmonary nodules with noninvasive CyPath® Lung testing. Register now at https://t.co/T8CRnmUNVc

#LungCancer #PulmonaryNodules #EarlyDetection #CyPathLung #oncology

[bioAffinity Technologies @bioAffinity]

CyPath® Lung:
·��      Noninvasive
·       Real-time results
·       Potential healthcare savings

#ATS2026 #CyPathLung #lungcancer #pulmonology #flowcytometry

[bioAffinity Technologies @bioAffinity]

When lung nodules fall into a gray area, clinicians need more insight. CyPath® Lung provides actionable results that support confident decisions about next steps, helping ensure patients receive timely, appropriate care.

https://t.co/Okp2Bq5YTn $BIAF

[bioAffinity Technologies @bioAffinity]

bioAffinity Technologies CEO Maria Zannes presented at the Veterans Research Symposium on Capitol Hill, highlighting our clinical trial validating CyPath® Lung for military and VA centers, partially funded by the John P. Murtha Cancer Center Program.

Thank you @NAVREF! $BIAF

[bioAffinity Technologies @bioAffinity]

Early insight matters. CyPath® Lung provides actionable diagnostic information on pulmonary nodules, helping clinicians decide when to intervene and when watchful waiting is appropriate.

Supporting faster, informed care. https://t.co/Okp2Bq5YTn $BIAF

[bioAffinity Technologies @bioAffinity]

CyPath® Lung achieved record monthly unit sales in April 2026, with volume increasing nearly 300% compared to April 2025, reflecting accelerating physician adoption and expanding clinical use.

Read the release: https://t.co/kN9gOdqxhA $BIAF

[bioAffinity Technologies @bioAffinity]

bioAffinity Technologies reported first quarter 2026 results and continued expanding adoption and clinical use of CyPath® Lung.

CyPath® Lung unit sales increased 146% year over year in Q1 2026, reflecting accelerated physician adoption. Read more: https://t.co/bAPcGzQ28Z $BIAF

[bioAffinity Technologies @bioAffinity]

CyPath® Lung provides clinicians with diagnostic insight, supporting timely decisions, more informed discussions and shared decision-making between physicians and their patients with pulmonary nodules.

More information can lead to more confident care. $BIAF